Remix Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
56
- Latest Deal Type
-
PIPE
- (In Progress)
- Latest Deal Amount
-
$100M
- Investors
-
13
Remix Therapeutics General Information
Description
ReMix Therapeutics Inc is a clinical-stage biotechnology company focused on developing small molecule therapeutics to modulate ribonucleic acid (RNA) processing and address the underlying drivers of disease. Its flagship program, REM-422, is an investigational oral mRNA degrader targeting the MYB oncogenic transcription factor, which is being developed for the treatment of adenoid cystic carcinoma (ACC), acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and other cancers.
Contact Information
Website
www.remixtx.comCorporate Office
- 100 Forge Road
- Suite 400
- Watertown, MA 02472
- United States
Corporate Office
- 100 Forge Road
- Suite 400
- Watertown, MA 02472
- United States
Remix Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. PIPE | 24-Jun-2026 | $100M | In Progress | Clinical Trials - General | ||
| 4. Reverse Merger | 24-Jun-2026 | Announced | Clinical Trials - General | |||
| 3. Later Stage VC | 03-Jan-2024 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series B) | 24-Mar-2022 | $70M | $153M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 08-Dec-2020 | $83M | $83M | Completed | Clinical Trials - General |
Remix Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 17,964,705 | $0.000100 | 8% | $0.95 | $0.95 | 1x | $0.95 | 17.05% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Remix Therapeutics Comparisons
Industry
Financing
Details
Remix Therapeutics Competitors (4)
One of Remix Therapeutics’s 4 competitors is Skyhawk Therapeutics, a Venture Capital-Backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Skyhawk Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
| Ribometrix | Venture Capital-Backed | Durham, NC | ||||
| Arrakis Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
| PTC Therapeutics | Formerly VC-backed | Warren, NJ |
Remix Therapeutics Patents
Remix Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026227027-A1 | Methods for identifying and treating cancer | Pending | 25-Apr-2025 | ||
| WO-2026128832-A2 | Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases | Pending | 12-Dec-2024 | ||
| WO-2026128832-A3 | Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases | Pending | 12-Dec-2024 | ||
| WO-2025245472-A1 | Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases | Pending | 24-May-2024 | ||
| WO-2025227032-A1 | Methods for degradation of cyclin k and inhibition of cyclin dependent kinases | Pending | 26-Apr-2024 | C07D403/10 |
Remix Therapeutics Signals
Remix Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Willett Advisors | Family Office | Minority | ||
| WTT Investment | Family Office | Minority | ||
| Surveyor Capital | Hedge Fund | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| ARCH Venture Partners | Venture Capital | Minority |
Remix Therapeutics Acquisitions (1)
Remix Therapeutics’s most recent deal was a Merger/Acquisition with Passage Bio. The deal was made on 24-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Passage Bio | 24-Jun-2026 | Merger/Acquisition | Drug Discovery |
Remix Therapeutics FAQs
-
When was Remix Therapeutics founded?
Remix Therapeutics was founded in 2019.
-
Where is Remix Therapeutics headquartered?
Remix Therapeutics is headquartered in Watertown, MA.
-
What is the size of Remix Therapeutics?
Remix Therapeutics has 56 total employees.
-
What industry is Remix Therapeutics in?
Remix Therapeutics’s primary industry is Drug Discovery.
-
Is Remix Therapeutics a private or public company?
Remix Therapeutics is a Private company.
-
What is Remix Therapeutics’s current revenue?
The current revenue for Remix Therapeutics is .
-
How much funding has Remix Therapeutics raised over time?
Remix Therapeutics has raised $213M.
-
Who are Remix Therapeutics’s investors?
Willett Advisors, WTT Investment, Surveyor Capital, Alexandria Venture Investments, and ARCH Venture Partners are 5 of 13 investors who have invested in Remix Therapeutics.
-
Who are Remix Therapeutics’s competitors?
Skyhawk Therapeutics, Ribometrix, Arrakis Therapeutics, and PTC Therapeutics are competitors of Remix Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process